101 Therapeutics to Present Phase 2/3 Data on Macrophage-Targeted, Steroid-Sparing Glucocorticoid 101-PGC-005 at ACR Convergence 2026

Posted on by sHq_LoGiNz

ENGLEWOOD, N.J.–(BUSINESS WIRE)–CD206-targeted glucocorticoid 101-PGC-005 beat dexamethasone in 309-patient Phase 2/3 trial (HR 2.31); steroid-sparing data at ACR Poster 0122, Nov 8

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.